Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

New center will use cutting-edge AI to accelerate the creation of life-saving medicines AI Small Molecule Drug Discovery Center Photo 1 Left to Right: Ethan Grimes, BS, and Paul Morgan, MD, conduct ...

We may make money when you click on links to our partners. Learn More. AI drug design and development company Isomorphic Labs announced on Monday that it raised $600 million in its first external ...

Although still under refinement, ASERIA represents a significant step towards integrating AI more effectively into drug design. The final presentation of the session was left to Matt Armstrong ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue on its mission to create new drugs and medicines using AI.

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

The funding will accelerate further development of Isomorphic’s AI drug design engine and support the company’s goal of bringing its discovered drugs to clinical trials. Isomorphic Labs was ...